ArticlePharmaceutics2019
Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Insights into recent advancements in human and animal rotavirus vaccines: Exploring new frontiers.Virologica Sinica · 2025Review
- Noroviruses: Evolutionary Dynamics, Epidemiology, Pathogenesis, and Vaccine Advances-A Comprehensive Review.Vaccines · 2024Review
- Expression and Purification of Porcine Rotavirus Structural Proteins in Silkworm Larvae as a Vaccine Candidate.Molecular biotechnology · 2023Article
- Recent advances in expression and purification strategies for plant made vaccines.Frontiers in plant science · 2023Review
- Plant-Derived Human Vaccines: Recent Developments.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.Archives of virology · 2022Review
- Plant-Based Vaccines: Antigen Design, Diversity, and Strategies for High Level Production.Vaccines · 2022Review
- Epidemiology and evolution of Norovirus in China.Human vaccines & immunotherapeutics · 2021Review
- Transient protein expression systems in plants and their applications.Plant biotechnology (Tokyo, Japan) · 2021Article
- Advances in Human Norovirus Vaccine Research.Vaccines · 2021Review
- Alfalfa Plants (Medicago sativa L.) Expressing the 85B (MAP1609c) Antigen of Mycobacterium avium subsp. paratuberculosis Elicit Long-Lasting Immunity in Mice.Molecular biotechnology · 2021Article
- Recent advances in human norovirus research and implications for candidate vaccines.Expert review of vaccines · 2020Review
- Norovirus Vaccine: Priorities for Future Research and Development.Frontiers in immunology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotaviruses (RVs) and noroviruses (NoVs) are major causes of childhood acute gastroenteritis. During development of a combination vaccine based on NoV virus-like particles (VLP) and RV VP6 produced in baculovirus expression system in insect cells, a dual role of VP6 as a vaccine antigen and an adjuvant for NoV-specific immune responses was discovered. Here the VP6 adjuvant effect on bivalent GI.4 and GII.4-2006a NoV VLPs produced in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.